LifeMD (LFMD)

What Moves the Stock

1. 01GLP-1 regulatory developments - FDA enforcement actions on compounded semaglutide/tirzepatide availability and state pharmacy board restrictions
2. 02Patient acquisition costs and marketing efficiency metrics - CAC trends, conversion rates from digital advertising, organic vs paid traffic mix
3. 03Prescription volume growth in weight management category - new patient adds, retention rates, average revenue per user expansion
4. 04Competitive dynamics from branded GLP-1 manufacturers (Novo Nordisk, Eli Lilly) expanding supply and launching lower-cost options
5. 05Reimbursement landscape changes - potential insurance coverage expansion for obesity medications affecting DTC demand
6. 06Weight management prescriptions (estimated 40-50% of revenue, primarily compounded GLP-1 medications like semaglutide)
7. 07Men's health treatments including ED medications and testosterone therapy (estimated 20-25%)
8. 08Dermatology and skincare prescription products (estimated 15-20%)

LFMD Chart

My Notes

• growth - Investors are attracted to 39.3% revenue growth and exposure to the high-growth GLP-1 weight management market despite…
• Rising rates negatively impact valuation multiples for unprofitable growth companies, compressing the 0.6x P/S multiple further.
• Watch on earnings: FDA enforcement actions and guidance on compounded GLP-1 medication availability, Branded semaglutide/tirzepatide supply status and pricing from Novo Nordisk and Eli Lilly, Monthly active patient count and cohort retention rates by therapeutic category.